Maynard Um
-
-
-
-
-
-
-
UroGen Pharma (URGN) PT Raised to $45 at H.C. Wainwright
-
-
-
-
-
-
-
UroGen Pharma (URGN) Misses Q4 EPS by 6c
-
-
-
-
-
-
-
UroGen publishes clinical review of ZUSDURI for bladder cancer treatment
-
-
-
-
-
-
-
Increasing unusual put option volume: AEHR PL PRMB AGNC URGN
-
-
-
-
-
-
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN
-
-
-
-
-
-
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN
-
-
-
-
-
-
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
-
404,882 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

